Long‐term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow‐up for 52 weeks (P06125)—Secondary publication

Long‐term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow‐up for 52 weeks (P06125)—Secondary publication

Abstract After completion of a 6‐week double‐blind trial of asenapine sublingual tablets (10 or 20 mg/day) versus placebo in Asian patients with acute exacerbation of schizophrenia, including Japanese patients, this open‐label study evaluated the safety and efficacy of a 52‐week treatment with asena...

Full description

Bibliographic Details
Main Authors: Toshihiko Kinoshita, Yoshiteru Takekita, Shuichi Hiraoka, Fumihiro Tamura, Yasuhiro Iwama
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Neuropsychopharmacology Reports
Subjects:
asenapine
clinical trial
schizophrenia
Online Access:https://doi.org/10.1002/npr2.12342

Similar Items

Similar Items